Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc.(INBX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$83.3
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INBX

11/13/2026: INBX (1-star) is currently NOT-A-BUY. Pass it for now.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in novel biologic therapeutics developed through proprietary modular protein engineering platforms. The company's primary strength lies in its promising oncology pipeline candidates, notably INBRX-109 and INBRX-106, which target high-unmet-need cancers. Its primary growth story centers on successful clinical trial readouts and potential biopharmaceutical partnerships. However, the company faces significant risks common to clinical-stage biotech firms, including ongoing cash burn, regulatory hurdles, and lack of commercial product revenue. The stock suits growth-oriented investors with high risk tolerance who are monitoring clinical milestones and trial updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveHigh-growth potential tied to clinical pipeline readouts and novel biologic platforms.
Momentum investorStrong fit while signal remains positiveStock price can experience rapid rallies or pullbacks around clinical data catalysts and trial updates.
Value investorWeak fitLack of consistent earnings and commercial revenue makes traditional value metrics inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital for drug development.
Low-risk investorWeak fitClinical-stage biotechnology carries inherent binary trial risks and high price volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotechnology stocks experience sharp price movements driven by clinical trial news and regulatory updates.
Valuation riskHighValuations depend on future clinical success rather than current earnings or cash flows.
Competition risk (biotech clinical competition)Medium / highAlternative therapies developed by larger competitors could outpace or surpass Inhibrx's candidates.
Business qualityMediumThe company features sophisticated protein engineering platforms but lacks a diversified commercial product portfolio.
Dividend incomeLow / noneNo cash dividends are paid to shareholders.
Execution riskHighSuccess relies entirely on clinical trial execution, regulatory approvals, and eventual commercialization.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.23B USD
Price to earnings Ratio -
1Y Target Price 266.67
Price to earnings Ratio -
1Y Target Price 266.67
Volume (30-day avg) 268.9K shares
Beta 4.04
52 Weeks Range 57.30 - 155.29
Updated Date 11/15/2026
52 Weeks Range 57.30 - 155.29
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -8.88

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 29.71%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INBX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
INBX has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, strong revenue growth (+550.0%) is partially offset by negative earnings growth (-108.3%), weak cash generation (FCF margin -9986.5%), weak profitability (net margin -10773.5%).

Financial Health Rating

★★★★★
INBX's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 67.6%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is INBX's strongest growth driver at +550.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+34.1%, solid) is also solid, while earnings growth (-108.3%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 88.6% and approximately 62.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 23.31% supports management-shareholder alignment.

Top 5 Institutional Investors

Morgan Stanley - Brokerage Accounts 8.89%
Perceptive Advisors LLC 8.82%
Sanofi 7.87%
Viking Global Investors LP 7.64%
HighTower Advisors, LLC 5.92%

Unit Economics (Per $1K Revenue)

★★★★★
INBX generates approximately $-910 of gross profit, $-103,865 of operating income, and $-99,865 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
INBX has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Licensing and CollaborationsUpfront license fees, milestone payments, and research funding from pharmaceutical partners.Currently, revenue is intermittent and dependent on partnership agreements rather than steady product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.27B
Price to Sales(TTM) 612.99
Enterprise Value 1.27B
Price to Sales(TTM) 612.99
Enterprise Value to Revenue 1128.34
Enterprise Value to EBITDA 0.02
Shares Outstanding 14.72M
Shares Floating 9.16M
Shares Outstanding 14.72M
Shares Floating 9.16M
Percent Insiders 23.31
Percent Institutions 88.56

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.